思觉失调症药物市场规模、份额、成长分析、按药物类别、按治疗、按分销管道、按地区 - 行业预测，2024-2031 年

2022年全球思觉失调症药物市场规模为75亿美元，从2023年的79亿美元成长到2031年的119.4亿美元，复合年增长率预计将维持在5.3%。

思觉失调症对生活的许多重要领域产生重大影响，包括人际关係、家庭关係、教育和就业，并且与过早死亡的风险增加有关，比一般人高两到三倍。此病影响全球约2,400万人，占人口的0.32%，成人盛行率高达0.45%。尤其是，此病在男性的发生率是女性的1.4倍，发病高峰年龄为男性20至28岁，女性25至32岁。由于有利的医疗改革、人口老化、健康意识的提高、具有成本效益的解决方案等，印度和中国的新兴市场为思觉失调症药物市场提供了巨大的成长机会。这种成长轨迹在亚太地区尤其明显，儘管存在挑战，包括欠发达地区缺乏知名度，阻碍了市场扩张。同时，美国思觉失调症药物市场预计在即将到来的预测期内将保持持续的复合年增长率。这些见解为思觉失调症治疗领域的相关人员带来了光明的前景，在全球不同程度的意识和准备情况下提供了创新和扩大影响力的途径。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• PESTEL分析
• 价格分析

思觉失调症药物市场：依药物类别

• 市场概况
• 第二代抗精神病药
  • Risperdal（Risperidone）
  • Invega（帕潘立酮）
  • Zyprexa（Olanzapine）
  • Geodon（齐拉西酮）
  • Seroquel（Quetiapine）
  • 拉图达（Lurasidone）
  • Aristada（Aripiprazole哌唑）
  • Fanapt（Iloperidone）
  • 萨弗里斯（Asenapine）
  • Vreilor（Cariprazine）
• 第三代抗精神病药
  • Abilify（Aripiprazole）
• 其他的
  • 第一代抗精神病药
  • 非专利的

思觉失调症药物市场：依治疗分类

• 市场概况
• 口服抗精神病药
• 注射抗精神病药

思觉失调症管道

• 市场概况
• 医院药房
• 零售药房
• 网路药房
• 其他的

思觉失调症药物市场规模：按地区

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Johnson & Johnson（US）
• Bristol-Myers Squibb（US）
• Otsuka Pharmaceutical Co., Ltd.（Japan）
• AstraZeneca（UK）
• Sumitomo Dainippon Pharma（Japan）
• Eli Lilly and Company（US）
• Alkermes Plc（Ireland）
• Vanda Pharmaceuticals Inc.（US）
• Allergan（Ireland）
• Pfizer Inc.（US）
• H. Lundbeck A/S（Denmark）
• Janssen Pharmaceuticals, Inc.（US）
• Minerva Neurosciences（US）
• Reliance Life Sciences（India）
• Novartis AG（Switzerland）
• GlaxoSmithKline（UK）
• Merck KGaA（Germany）
• Takeda Pharmaceuticals（Japan）
• AbbVie（US）
• Acadia Pharmaceuticals（US）
• Karuna Therapeutics（US）

Global Schizophrenia Drugs Market size was valued at USD 7.50 billion in 2022 and is poised to grow from USD 7.90 billion in 2023 to USD 11.94 billion by 2031, growing at a CAGR of 5.3% in the forecast period (2024-2031).

Schizophrenia significantly impacts various critical areas of life, including personal relationships, family dynamics, education, and employment, leading to a heightened risk of premature death-two to three times higher than the general population. The condition affects approximately 24 million people globally, translating to 0.32% of the population, with a higher prevalence of 0.45% among adults. Notably, the disorder occurs 1.4 times more frequently in men than women, with peak onset ages ranging from 20 to 28 years for males and 25 to 32 years for females. Emerging markets in India and China present substantial growth opportunities for the schizophrenia drug market, driven by favorable healthcare reforms, an aging population, increasing health awareness, and cost-effective solutions. This growth trajectory is particularly strong in the Asia Pacific region, despite challenges such as a lack of awareness in underdeveloped areas hindering market expansion. Meanwhile, the US schizophrenia drug market is projected to maintain a sustainable compound annual growth rate (CAGR) in the upcoming forecast period. These insights indicate a promising landscape for stakeholders in the schizophrenia treatment sector, offering avenues for innovation and expanded reach amidst varying global awareness and preparedness levels.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Schizophrenia Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Schizophrenia Drugs Market Segmental Analysis

Global Schizophrenia Drugs Market is segmented on the drug class, treatment, distribution channel and region. By drug class, market is segmented into second-generation antipsychotics, third-generation antipsychotics, and others. By treatment, market is segmented into oral antipsychotics, and injectable antipsychotics. By distribution channel, market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Global Schizophrenia Drugs Market

The Global Schizophrenia Drugs market is poised for significant growth, driven by an increasing prevalence of schizophrenia and an escalating demand for improved healthcare infrastructure. As governments partner with healthcare facilities to enhance treatment safety and availability, more patients are receiving adequate therapeutic interventions. Ongoing clinical studies aimed at developing innovative drugs targeting novel molecular pathways are set to address pressing unmet needs in schizophrenia management. This proactive approach by pharmaceutical companies to explore new therapeutic avenues and strengthen their drug pipelines is expected to captivate both healthcare providers and patients, thus propelling the market forward.

Restraints in the Global Schizophrenia Drugs Market

The Global Schizophrenia Drugs market faces significant restraints that hinder its growth potential. A critical barrier is the insufficient awareness and understanding of mental health issues, particularly in developing countries, where stigma and lack of resources further complicate treatment accessibility. Furthermore, the high costs associated with schizophrenia medications and treatments limit patient access and reduce overall market demand. Additionally, adverse effects associated with many antipsychotic medications contribute to patients' reluctance to initiate or adhere to treatment regimens, undermining confidence in available therapies. Together, these factors create a challenging landscape that slows the overall expansion of the market.

Market Trends of the Global Schizophrenia Drugs Market

The Global Schizophrenia Drugs market is experiencing a transformative shift driven by an evolving understanding of the complex mechanisms underlying schizophrenia. With traditional views focusing on dopamine dysregulation now expanded to include multifaceted structural and chemical abnormalities, drug development is increasingly targeting novel pathways. Research is gaining momentum in exploring trace amine-associated receptors (TAARs), muscarinic receptors, and serotonergic receptors, which promise to offer safer and more effective therapeutic options. This diversification in targets is paving the way for innovative treatments, thus propelling market growth as pharmaceutical companies adapt to these advancements and strive to meet the evolving needs of patients globally.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree Of Competition
• Top Investment Pockets
• Ecosystem Of the Market
• PESTEL Analysis
• Pricing Analysis

Schizophrenia Drugs Market, By Drug Class

• Market Overview
• Second-Generation Antipsychotics
  • Risperdal (Risperidone)
  • Invega (Paliperidone)
  • Zyprexa (Olanzapine)
  • Geodon (Ziprasidone)
  • Seroquel (Quetiapine)
  • Latuda (Lurasidone)
  • Aristada (Aripiprazole Lauroxil)
  • Fanapt (Iloperidone)
  • Saphris (Asenapine)
  • Vraylar (Cariprazine)
• Third-Generation Antipsychotics
  • Abilify (Aripiprazole)
• Others
  • First-Generation Antipsychotics
  • Generics

Schizophrenia Drugs Market, By Treatment

• Market Overview
• Oral Antipsychotics
• Injectable Antipsychotics

Schizophrenia Drugs Market, By Distribution Channel

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Schizophrenia Drugs Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Dainippon Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkermes Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vanda Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Minerva Neurosciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reliance Life Sciences (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceuticals (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karuna Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments